Madrigal Pharmaceuticals (MDGL) Notes Payables (2015)

Madrigal Pharmaceuticals (MDGL) posted quarterly Notes Payables of $48.6 million for Q4 2015.

Madrigal Pharmaceuticals (MDGL) Notes Payables (2015) Analysis & Trends

Madrigal Pharmaceuticals (MDGL) has reported Notes Payables for 1 consecutive years, with $48.6 million the latest figure, recorded in Q4 2015.

  • In Q4 2015, Notes Payables changed N/A year-over-year to $48.6 million; the TTM figure through Dec 2015 stood at $48.6 million (changed N/A YoY), while the FY2015 annual figure was $48.6 million, changed N/A from the prior year.
  • Notes Payables was little changed at $48.6 million in Q4 2015 per MDGL's latest filing.
  • Across five years, Notes Payables topped out at $48.6 million in Q4 2015 and bottomed at $48.6 million in Q4 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Madrigal Pharmaceuticals 14.79 Bn 13.95 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2015 48.60 Mn